Zachary J Roberts, Incoming President and CEO at Allogene Therapeutics, shared a post on LinkedIn:
“Treating Cancer Before Relapse: The MRD Era Has Arrived
The FDA recently approved Genentech’s (Roche Group) Tecentriq® (atezolizumab) for patients with muscle-invasive bladder cancer who still have detectable tumor DNA in their blood after surgery – before recurrence can even be seen on scans. It marks the first FDA approval of a ctDNA MRD-guided therapy, moving cancer treatment closer to intervening on molecular evidence of disease rather than waiting for radiographic relapse. This is more than a bladder cancer breakthrough; it is a paradigm-shifting moment for oncology.
A new generation of blood tests known as minimal residual disease (MRD) assays can detect microscopic traces of cancer long before tumors appear on imaging. But detection alone is not enough. The Tecentriq approval is the first proof that these early molecular signals can be paired with an effective therapy to meaningfully improve patient outcomes.
Roche has helped establish the value of MRD-guided intervention. Allogene represents the leading edge of where this field is going next, using a highly sensitive assay to identify residual disease in blood cancer as part of first-line (1L) consolidation large B-cell lymphoma (LBCL) treatment to potentially prevent relapse at the earliest possible stage. Allogene is advancing that paradigm into 1L LBCL by using MRD to guide early therapeutic intervention.
In the ALPHA3 trial, ctDNA-based MRD detection is used to identify patients for treatment with an off-the-shelf allogeneic CAR T product. Early interim futility data are encouraging: 58.3% of MRD-positive patients treated with our investigational therapy cleared residual disease signals, compared with 16.7% under observation alone.
The MRD-guided era of oncology is here. And Allogene Therapeutics is in the pole position for blood cancer.”
Other articles about Minimal Residual Disease (MRD) on OncoDaily.